Skip to content

Paul Cumming

18 papers in the library · 285 citations · publishing 2004-2026

Papers

Sort Most recent Most cited

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [ 18 F]FDG-PET study

Universität Zürich, ZORA June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N -dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.5167/uzh-434709 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study.

Journal of Cerebral Blood Flow & Metabolism June 1, 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ayahuasca-oral DMT induces a psychedelic experience lasting 4-5 h. While some neuroimaging...

N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain

Neuropharmacology February 9, 2026 Mikael Palner, Elisabeth Kolesnik, Christina Baun et al.

Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...

N,N-dimethyltryptamine (DMT) is neither formed nor retained in serotonin terminals in the rat brain.

Open Access CRIS of the University of Bern February 9, 2026 Mikael Palner, Elisabeth Kolesnik, Christina Baun et al.

Mammalian brain may contain an endogenous pool of the psychedelic substance N,N-dimethyltryptamine (DMT), which may act as a co-transmitter with serotonin (5-HT). We tested the joint hypotheses. We tested the joint hypotheses that endogenous DMT would accumulate in rat brain after inhibiting monoamine oxidase with pargyline, whereas its acidic metabolite 3-indoleacetic acid (3-IAA) would...

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [¹⁸F]FDG-PET study

Repository for Publications and Research Data 2026 Klemens Egger, Robert Bozsak, Helena Aicher et al.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a psychedelic experience lasting 4–5 h. While some neuroimaging...

DOI: 10.3929/ethz-c-000801722 (opens in new tab) Harmine Placebo Neuroimaging Metabolite +9

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study

Research Square July 27, 2025 Klemens Egger, Robert Bozsak, Helena Aicher et al. 1 citation preprint

Abstract Classical psychedelics such N,N -dimethyltryptamine (DMT), psilocybin, and lysergic acid diethylamide (LSD) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine—mimicking the pharmacological profile of ayahuasca—oral DMT induces a...

DOI: 10.21203/rs.3.rs-7099164/v1 (opens in new tab) N-dimethyltryptamine Psychoactive compounds n Harmine Brain activity +6

Molecular brain imaging of psychedelic action.

International review of neurobiology 2025 Paul Cumming, Klemens Egger, Gitte M. Knudsen 2 citations

Molecular brain imaging by positron emission tomography (PET) and single photon emission computer-tomography (SPECT) entails the mapping of the cerebral distribution of radiopharmaceuticals that track physiological processes such as blood perfusion and glucose metabolism, or the abundance in brain of specific molecular targets such as neuroreceptors. PET and SPECT emerged as useful in vivo...

DOI: 10.1016/bs.irn.2025.02.005 (opens in new tab) Full text (opens in new tab) LSD Cerebral blood flow Metabolism Psychedelics: psilocybin +4

Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Cellular and Molecular Life Sciences September 10, 2024 Klemens Egger, Helena Aicher, Paul Cumming et al. 30 citations

The potent hallucinogen N,N-dimethyltryptamine (DMT) has garnered significant interest in recent years due to its profound effects on consciousness and its therapeutic psychopotential. DMT is an integral (but not exclusive) psychoactive alkaloid in the Amazonian plant-based brew ayahuasca, in which admixture of several β-carboline monoamine oxidase A (MAO-A) inhibitors potentiate the activity...

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.

Molecular Psychiatry September 1, 2023 Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff et al. 48 citations

Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...

Pharmacokinetic and Pharmacodynamic Interaction of the Ayahuasca Constituents Harmine and Dimethyltryptamine (DMT) in the Rat Brain

January 4, 2023 Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al. preprint

RationaleThe psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are attributed to the effects of N,N-dimethyltryptamine (DMT) at brain serotonin 5-HT2A receptors. To make oral DMT bioavailable, ayahuasca additionally contains reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine. However, there is lacking biochemical...

DOI: 10.31219/osf.io/cv6ey (opens in new tab) Ayahuasca Harmine Pharmacology Harmaline +5

A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.

Frontiers in Pharmacology 2023 Klemens Egger, Frederik Gudmundsen, Naja Støckel Jessen et al. 17 citations

Rationale: The psychedelic effects of the traditional Amazonian botanical decoction known as ayahuasca are often attributed to agonism at brain serotonin 5-HT2A receptors by N,N-dimethyltryptamine (DMT). To reduce first pass metabolism of oral DMT, ayahuasca preparations additionally contain reversible monoamine oxidase A (MAO-A) inhibitors, namely β-carboline alkaloids such as harmine....

Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca

Frontiers in Pharmacology May 2, 2022 Ilana Berlowitz, Klemens Egger, Paul Cumming 32 citations

The monoamine oxidases (MAOs) are flavin-containing amine oxidoreductases responsible for metabolism of many biogenic amine molecules in the brain and peripheral tissues. Whereas serotonin is the preferred substrate of MAO-A, phenylethylamine is metabolized by MAO-B, and dopamine and tyramine are nearly ambivalent with respect to the two isozymes. β-Carboline alkaloids such as harmine,...

DOI: 10.3389/fphar.2022.886408 (opens in new tab) Ayahuasca Serotonin Pharmacology Monoamine neurotransmitter +10

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

Molecules April 22, 2021 Paul Cumming, Milan Scheidegger, Dario Dornbierer et al. 45 citations

Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a...

DOI: 10.3390/molecules26092451 (opens in new tab) Action physics Drug action Pharmacology

Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis

Neuropsychopharmacology March 3, 2021 Nora Penzel, Linda A. Antonucci, Linda T. Betz et al. 18 citations

Cannabis use during adolescence is associated with an increased risk of developing psychosis. According to a current hypothesis, this results from detrimental effects of early cannabis use on brain maturation during this vulnerable period. However, studies investigating the interaction between early cannabis use and brain structural alterations hitherto reported inconclusive findings. We...

DOI: 10.1038/s41386-021-00977-9 (opens in new tab) Full text (opens in new tab) Psychosis Schizophrenia object-oriented programming Confounding Age of onset +4

A PET study of effects of chronic 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) on serotonin markers in Göttingen minipig brain

Synapse April 5, 2007 Paul Cumming, Mette Møller, Kjeld Benda et al. 28 citations

Abstract The psychostimulant 3,4‐methylendioxymethamphetamine (MDMA, “ecstasy”) evokes degeneration of telencephalic serotonin innervations in rodents, nonhuman primates, and human recreational drug users. However, there has been no alternative to nonhuman primates for studies of the cognitive and neurochemical consequences of serotonin depletion in a large‐bodied animal. Therefore, we used...

DOI: 10.1002/syn.20377 (opens in new tab) MDMA Ecstasy Neurochemical Serotonin transporter +3

Interaction between LSD and dopamine D2/3 binding sites in pig brain

Synapse 2005 Luciano Minuzzi, George G. Nomikos, Mark Wade et al. 25 citations

The psychoactive properties of the hallucinogen LSD have frequently been attributed to high affinity interactions with serotonin 5HT2 receptors in brain. Possible effects of LSD on dopamine D2/3 receptor availability have not previously been investigated in living brain. Therefore, we used PET to map the binding potential (pB) of [11C]raclopride in brain of three pigs, first in a baseline...

DOI: 10.1002/syn.20141 (opens in new tab) Serotonin Raclopride Dopamine receptor d2 Pharmacology +4

MDMA‐evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain

Synapse July 14, 2004 Pedro Rosa‐neto, Albert Gjedde, Aage Kristian Olsen Alstrup et al. 39 citations

Abstract Positron emission tomography (PET) studies with radiolabeled dopamine D 2 ‐like receptor ligands reveal d ‐amphetamine‐evoked increases in the competition from endogenous dopamine. However, the corresponding effects of methylenedioxymethamphetamine (MDMA, “Ecstasy”), which releases catecholamines and also serotonin, are unknown. Using PET, we measured the binding potentials ( pB s) of...